Kv8.2

1

Ng CA et al. Tyrosine residues from the S4-S5 linker of Kv11.1 channels are critical for slow deactivation.
J. Biol. Chem., 2016 Jun 17 , ().

2

Heide J et al. Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status.
Am J Psychiatry, 2016 Jan , 173 (53-9).

3

Gintant G et al. Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov, 2016 Feb 19 , ().

4

Ye F et al. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Toxins (Basel), 2016 , 8 ().

5

Arcangeli A et al. Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat., 2015 Jul-Aug , 21-22 (11-9).

6

Goodchild SJ et al. Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J., 2015 Mar 24 , 108 (1435-47).

7

Perissinotti LL et al. Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel.
Biophys. J., 2015 Mar 24 , 108 (1414-24).

8

Zhou FJ et al. Two New Classes of T-Type Calcium Channel Inhibitors with New Chemical Scaffolds from Ganoderma cochlear.
Org. Lett., 2015 Jun 19 , 17 (3082-5).

9

Männikkö R et al. Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol., 2015 Feb 12 , ().

10

Vijayvergiya V et al. Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices, 2015 Feb , 17 (12).

11

Gasparoli L et al. New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity.
Mol. Pharmacol., 2015 Feb , 87 (183-96).

12

Zhu W et al. Molecular motions that shape the cardiac action potential: Insights from voltage clamp fluorometry.
Prog. Biophys. Mol. Biol., 2015 Dec 25 , ().

13

Li X et al. Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
Arch. Toxicol., 2015 Dec 16 , ().

14

Kanters JK et al. Combined gating and trafficking defect in Kv11.1 manifests as a malignant long QT syndrome phenotype in a large Danish p.F29L founder family.
Scand. J. Clin. Lab. Invest., 2015 Dec , 75 (699-709).

15

Yu Z et al. Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers.
J. Med. Chem., 2015 Aug 13 , 58 (5916-29).

16

Wang J et al. MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.
J. Mol. Neurosci., 2015 Apr , 55 (985-94).

17

Stimers JR et al. Overexpression of the Large-Conductance, Ca2+-Activated K+ (BK) Channel Shortens Action Potential Duration in HL-1 Cardiomyocytes.
PLoS ONE, 2015 , 10 (e0130588).

18

Pedersen PJ et al. Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium.
PLoS ONE, 2015 , 10 (e0138320).

19

Rast G et al. Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
J Pharmacol Toxicol Methods, 2014 Sep-Oct , 70 (182-7).

20

Ng CA et al. Multiple interactions between cytoplasmic domains regulate slow deactivation of Kv11.1 channels.
J. Biol. Chem., 2014 Sep 12 , 289 (25822-32).

21

Shopp GM et al. Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Anticancer Res., 2014 Sep , 34 (4733-40).

22

Gong Q et al. Upregulation of functional Kv11.1 isoform expression by inhibition of intronic polyadenylation with antisense morpholino oligonucleotides.
J. Mol. Cell. Cardiol., 2014 Nov , 76 (26-32).

23

Frolov RV et al. Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol., 2014 May 5 , 730 (61-71).

24

Shi S et al. Chronic N-Methyl-d-Aspartate Receptor Activation Induces Cardiac Electrical Remodeling and Increases Susceptibility to Ventricular Arrhythmias.
Pacing Clin Electrophysiol, 2014 May 30 , ().

25

Ke Y et al. Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.
J. Biol. Chem., 2014 May 16 , 289 (13782-91).

26

Hill AP et al. Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol., 2014 May , 85 (769-76).

27

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

28

Radresa O et al. Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen, 2014 Jan 24 , ().

29

Stockman A et al. Cone dystrophy with "supernormal" rod ERG: psychophysical testing shows comparable rod and cone temporal sensitivity losses with no gain in rod function.
Invest. Ophthalmol. Vis. Sci., 2014 Feb , 55 (832-40).

30

Gong Q et al. Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet, 2014 Aug , 7 (482-90).

31

Schlichter LC et al. Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domain.
PLoS ONE, 2014 , 9 (e90024).

32

Munoz C et al. Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem., 2014 , 33 (491-500).

33

Nielsen JB et al. Gain-of-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation.
Biomark Med, 2014 , 8 (557-70).

34

Aslanidis A et al. RETINA-specific expression of Kcnv2 is controlled by cone-rod homeobox (Crx) and neural retina leucine zipper (Nrl).
Adv. Exp. Med. Biol., 2014 , 801 (31-41).

35

Staudacher I et al. HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells.
PLoS ONE, 2014 , 9 (e88164).

36

Anderson CL et al. Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
Nat Commun, 2014 , 5 (5535).

37

Schweigmann U et al. Elevated heart rate triggers action potential alternans and sudden death. translational study of a homozygous KCNH2 mutation.
PLoS ONE, 2014 , 9 (e103150).

38

Lu J et al. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.
PLoS ONE, 2014 , 9 (e115648).

39

Rampe D et al. A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (13-22).

40

Hedley PL et al. The Role of CAV3 in Long QT Syndrome: Clinical and Functional Assessment of a Caveolin-3/Kv11.1 Double Heterozygote Versus Caveolin-3 Single Heterozygote.
Circ Cardiovasc Genet, 2013 Sep 10 , ().

41

Cheng YM et al. Functional interactions of voltage sensor charges with an S2 hydrophobic plug in hERG channels.
J. Gen. Physiol., 2013 Sep , 142 (289-303).

42

Perry MD et al. Hydrophobic interactions between the voltage sensor and pore mediate inactivation in Kv11.1 channels.
J. Gen. Physiol., 2013 Sep , 142 (275-88).

43

Andreasen L et al. Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol, 2013 Oct , 29 (1234-40).

44

Ayon RJ et al. Mutant hERG channel traffic jam. Focus on "Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum".
Am. J. Physiol., Cell Physiol., 2013 Nov 1 , 305 (C916-8).

45

Smith JL et al. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
Am. J. Physiol., Cell Physiol., 2013 Nov 1 , 305 (C919-30).

46

Sharon D et al. Recognizing the KCNV2-related retinal phenotype. Author reply.
Ophthalmology, 2013 Nov , 120 (e80).

47

Khan AO Recognizing the KCNV2-related retinal phenotype.
Ophthalmology, 2013 Nov , 120 (e79-80).

48

Zelinger L et al. Cone dystrophy with supernormal rod response: novel KCNV2 mutations in an underdiagnosed phenotype.
Ophthalmology, 2013 Nov , 120 (2338-43).

49

Leanza L et al. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Curr. Pharm. Des., 2013 May 16 , ().

50

McBride CM et al. Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
J. Membr. Biol., 2013 May , 246 (355-64).

51

Kazmierczak M et al. External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor.
J. Gen. Physiol., 2013 Jun , 141 (721-35).

52

Huang L et al. Screening for variants in 20 genes in 130 unrelated patients with cone-rod dystrophy.
Mol Med Rep, 2013 Jun , 7 (1779-85).

53

Kiss T et al. Identification of diterpene alkaloids from Aconitum napellus subsp. firmum and GIRK channel activities of some Aconitum alkaloids.
Fitoterapia, 2013 Jul 19 , ().

54

Takanari H et al. Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res., 2013 Jul 1 , 99 (203-14).

55

Vincent A et al. Pathognomonic (diagnostic) ERGs. A review and update.
Retina (Philadelphia, Pa.), 2013 Jan , 33 (5-12).

56

Ritter M et al. Coexistence of KCNV2 associated cone dystrophy with supernormal rod electroretinogram and MFRP related oculopathy in a Turkish family.
Br J Ophthalmol, 2013 Feb , 97 (169-73).

57

Grigg JR et al. The importance of electrophysiology in revealing a complete homozygous deletion of KCNV2.
J AAPOS, 2013 Dec , 17 (641-3).

58

K E Y et al. Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions.
Biochem. J., 2013 Aug 15 , 454 (69-77).

59

Perry MD et al. Pore helices play a dynamic role as integrators of domain motion during Kv11.1 channel inactivation gating.
J. Biol. Chem., 2013 Apr 19 , 288 (11482-91).

60

Crotti L et al. Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA, 2013 Apr 10 , 309 (1473-82).

61

Vincent A et al. Phenotypic characteristics including in vivo cone photoreceptor mosaic in KCNV2-related "cone dystrophy with supernormal rod electroretinogram".
Invest. Ophthalmol. Vis. Sci., 2013 , 54 (898-908).

62

Fujinami K et al. Molecular characteristics of four Japanese cases with KCNV2 retinopathy: report of novel disease-causing variants.
Mol. Vis., 2013 , 19 (1580-90).

63

Ng CA et al. C-Terminal β9-Strand of the Cyclic Nucleotide-Binding Homology Domain Stabilizes Activated States of Kv11.1 Channels.
PLoS ONE, 2013 , 8 (e77032).

64

Abderemane-Ali F et al. Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem., 2012 Oct 19 , 287 (36158-67).

65

Giudicessi JR et al. Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome.
Circ Cardiovasc Genet, 2012 Oct 1 , 5 (519-28).

66

Hölter P et al. The retinal clock drives the expression of Kcnv2, a channel essential for visual function and cone survival.
Invest. Ophthalmol. Vis. Sci., 2012 Oct , 53 (6947-54).

67

Donovan AJ et al. LQT2 Mutation on the Kv11.1 Ion Channel Inhibits Current Activity by Ablating a PKCα Consensus Site.
, 2012 May 31 , ().

68

Khan AO et al. 'Cone dystrophy with supranormal rod response' in children.
Br J Ophthalmol, 2012 Mar , 96 (422-6).

69

Vandenberg JI et al. hERG K(+) channels: structure, function, and clinical significance.
Physiol. Rev., 2012 Jul , 92 (1393-478).

70

Hjaeresen ML et al. Time course and duration of changes in Kv7.2 and Kv11.1 mRNA expression in the hippocampus and piriform cortex following electroconvulsive stimulations.
Brain Stimul, 2012 Jan , 5 (55-60).

71

Sergouniotis PI et al. High-resolution optical coherence tomography imaging in KCNV2 retinopathy.
Br J Ophthalmol, 2012 Feb , 96 (213-7).

72

Smith KE et al. Functional analysis of missense mutations in Kv8.2 causing cone dystrophy with supernormal rod electroretinogram.
J. Biol. Chem., 2012 Dec 21 , 287 (43972-83).

73

Schweikart K et al. The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.
Toxicol In Vitro, 2012 Dec 20 , 27 (745-751).

74

Balijepalli SY et al. Mechanism of Loss of Kv11.1 K+ Current in Mutant T421M-Kv11.1-Expressing Rat Ventricular Myocytes: Interaction of Trafficking and Gating.
Circulation, 2012 Dec 11 , 126 (2809-18).

75

Thiadens AA et al. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy.
Ophthalmology, 2012 Apr , 119 (819-26).

76

Misner DL et al. Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.
Br. J. Pharmacol., 2012 Apr , 165 (2771-86).

77

Cheng YM et al. Voltage-dependent gating of HERG potassium channels.
Front Pharmacol, 2012 , 3 (83).

78

Moreno C et al. Polyunsaturated Fatty acids modify the gating of kv channels.
Front Pharmacol, 2012 , 3 (163).

79

Bilet A et al. Effects of the small molecule HERG activator NS1643 on Kv11.3 channels.
PLoS ONE, 2012 , 7 (e50886).

80

Zobor D et al. Rod and cone function in patients with KCNV2 retinopathy.
PLoS ONE, 2012 , 7 (e46762).

81

Heide J et al. The schizophrenia-associated Kv11.1-3.1 isoform results in reduced current accumulation during repetitive brief depolarizations.
PLoS ONE, 2012 , 7 (e45624).

82

Aoki Y et al. Role of ion channels in sepsis-induced atrial tachyarrhythmias in guinea pigs.
, 2011 Nov 3 , ().

83

Friedburg C et al. Long-term follow-up of the human phenotype in three siblings with cone dystrophy associated with a homozygous p.G461R mutation of KCNV2.
Invest. Ophthalmol. Vis. Sci., 2011 Nov , 52 (8621-9).

84

Jorge BS et al. Voltage-gated potassium channel KCNV2 (Kv8.2) contributes to epilepsy susceptibility.
, 2011 Mar 14 , ().

85

Amorós I et al. Functional effects of a missense mutation in HERG associated with type 2 long QT syndrome.
Heart Rhythm, 2011 Mar , 8 (463-70).

86

Shao L et al. Synthesis and Pharmacological Characterization of Bicyclic Triple Reuptake Inhibitor 3-Aryl Octahydrocyclopenta[c]pyrrole Analogues.
, 2011 Jul 8 , ().

87

Firth AL et al. Functional ion channels in human pulmonary artery smooth muscle cells: Voltage-dependent cation channels.
Pulm Circ, 2011 Jan 1 , 1 (48-71).

88

Gintant G An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Pharmacol. Ther., 2011 Feb , 129 (109-19).

89

Bentzen BH et al. Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.
J. Cardiovasc. Pharmacol., 2011 Feb , 57 (223-30).

90

Arcangeli A et al. Targeting Ion Channels in Leukemias: A New Challenge for Treatment.
, 2011 Dec 29 , ().

91

Davies MR et al. An In silico Canine Cardiac Midmyocardial Action Potential Duration Model as a Tool for Early Drug Safety Assessment.
, 2011 Dec 23 , ().

92

Wissinger B et al. Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response.
Hum. Mutat., 2011 Dec , 32 (1398-406).

93

Bett GC et al. Models of HERG gating.
Biophys. J., 2011 Aug 3 , 101 (631-42).

94

Jehle J et al. Novel roles for hERG K(+) channels in cell proliferation and apoptosis.
Cell Death Dis, 2011 , 2 (e193).

95

Mihic A et al. Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation.
PLoS ONE, 2011 , 6 (e18273).

96

Banderali U et al. Curcumin Blocks Kv11.1 (erg) Potassium Current and Slows Proliferation in the Infant Acute Monocytic Leukemia Cell line THP-1.
Cell. Physiol. Biochem., 2011 , 28 (1169-80).

97

Cordeiro S et al. Expression pattern of Kv11 (Ether à-go-go-related gene; erg) K+ channels in the mouse retina.
PLoS ONE, 2011 , 6 (e29490).

98

Shao L et al. Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor.
, 2010 Oct 28 , ().

99

Larsen AP et al. Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.
Br. J. Pharmacol., 2010 Oct , 161 (614-28).

100

Larsen AP Role of ERG1 isoforms in modulation of ERG1 channel trafficking and function.
Pflugers Arch., 2010 Oct , 460 (803-12).

101

Angus D et al. The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain.
, 2010 Nov 6 , ().

102

Subbotina J et al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations.
Proteins, 2010 Nov 1 , 78 (2922-34).

103

Littink KW et al. Homozygosity mapping in patients with cone-rod dystrophy: novel mutations and clinical characterizations.
Invest. Ophthalmol. Vis. Sci., 2010 Nov , 51 (5943-51).

104

Chen J et al. Post-transcriptional control of HERG potassium channel protein by {alpha}-adrenergic receptor stimulation.
, 2010 May 12 , ().

105

Obers S et al. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Naunyn Schmiedebergs Arch. Pharmacol., 2010 May , 381 (385-400).

106

Beacham DW et al. Cell-Based Potassium Ion Channel Screening Using the FluxORTM Assay.
, 2010 Mar 5 , ().

107

Zhou Q et al. Regulation of the voltage-insensitive step of HERG activation by extracellular pH.
Am. J. Physiol. Heart Circ. Physiol., 2010 Jun , 298 (H1710-8).

108

Andersen MK et al. Oligocone trichromacy: clinical and molecular genetic investigations.
Invest. Ophthalmol. Vis. Sci., 2010 Jan , 51 (89-95).

109

Robson AG et al. "Cone dystrophy with supernormal rod electroretinogram": a comprehensive genotype/phenotype study including fundus autofluorescence and extensive electrophysiology.
Retina (Philadelphia, Pa.), 2010 Jan , 30 (51-62).

110

Cordeiro JM et al. Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2.
Can. J. Physiol. Pharmacol., 2010 Dec , 88 (1181-90).

111

Rodriguez N et al. Phosphatidylinositol-4,5-Bisphosphate (PIP(2)) Stabilizes the Open Pore Conformation of the Kv11.1 (hERG) Channel.
, 2010 Aug 9 , 99 (1110-1118).

112

Muskett FW et al. Resonance assignment and secondary structure prediction of the N-terminal domain of hERG (Kv11.1).
, 2010 Aug 14 , ().

113

Larsen AP et al. Pharmacological activation of IKr impairs conduction in guinea pig hearts.
J. Cardiovasc. Electrophysiol., 2010 Aug 1 , 21 (923-9).

114

Atalar F et al. Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.
Behav Brain Funct, 2010 , 6 (27).

115

Hunter C et al. Selective inhibitors of Kv11.1 regulate IL-6 expression by macrophages in response to TLR/IL-1R ligands.
ScientificWorldJournal, 2010 , 10 (1580-96).

116

Bergren SK et al. Fine mapping of an epilepsy modifier gene on mouse Chromosome 19.
Mamm. Genome, 2009 Jun , 20 (359-66).

117

Zankov DP et al. Adrenergic regulation of the rapid component of delayed rectifier K+ current: implications for arrhythmogenesis in LQT2 patients.
Heart Rhythm, 2009 Jul , 6 (1038-46).

118

Einarsen K et al. Functional properties of human neuronal Kv11 channels.
Pflugers Arch., 2009 Aug , 458 (689-700).

119

Grunnet M et al. hERG1 channel activators: a new anti-arrhythmic principle.
Prog. Biophys. Mol. Biol., 2008 Oct-Nov , 98 (347-62).

120

Gentile S et al. The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.
Proc. Natl. Acad. Sci. U.S.A., 2008 Sep 23 , 105 (14704-8).

121

Wang X et al. Kv11.1 channel subunit composition includes MinK and varies developmentally in mouse cardiac muscle.
Dev. Dyn., 2008 Sep , 237 (2430-7).

122

Zhang DY et al. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.
Cell. Signal., 2008 Oct , 20 (1815-21).

123

Bowlby MR et al. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.
Curr. Drug Metab., 2008 Nov , 9 (965-70).

124

Claassen S et al. Electrophysiological and fluorescence microscopy studies with HERG channel/EGFP fusion proteins.
J. Membr. Biol., 2008 Mar , 222 (31-41).

125

Hjaeresen ML et al. Chronic electroconvulsive stimulation but not chronic restraint stress modulates mRNA expression of voltage-dependent potassium channels Kv7.2 and Kv11.1 in the rat piriform cortex.
Brain Res., 2008 Jun 27 , 1217 (179-84).

126

Ben Salah S et al. Novel KCNV2 mutations in cone dystrophy with supernormal rod electroretinogram.
Am. J. Ophthalmol., 2008 Jun , 145 (1099-106).

127

Wissinger B et al. Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2.
Invest. Ophthalmol. Vis. Sci., 2008 Feb , 49 (751-7).

128

Chtcheglova LA et al. Localization of the ergtoxin-1 receptors on the voltage sensing domain of hERG K+ channel by AFM recognition imaging.
Pflugers Arch., 2008 Apr , 456 (247-54).

129

Lundby A et al. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation.
Cell. Physiol. Biochem., 2008 , 21 (47-54).

130

Balijepalli RC et al. Kv11.1 (ERG1) K+ channels localize in cholesterol and sphingolipid enriched membranes and are modulated by membrane cholesterol.
Channels (Austin), 2007 Jul-Aug , 1 (263-72).

131

Czirják G et al. Characterization of the heteromeric potassium channel formed by kv2.1 and the retinal subunit kv8.2 in Xenopus oocytes.
J. Neurophysiol., 2007 Sep , 98 (1213-22).

132

Thiagalingam S et al. Novel mutations in the KCNV2 gene in patients with cone dystrophy and a supernormal rod electroretinogram.
Ophthalmic Genet., 2007 Sep , 28 (135-42).

133

Bai X et al. Electrophysiological properties of human adipose tissue-derived stem cells.
Am. J. Physiol., Cell Physiol., 2007 Nov , 293 (C1539-50).

134

Tang Q et al. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells.
Biochem. Pharmacol., 2007 Dec 3 , 74 (1596-607).

135

Wu H et al. Mutations in the gene KCNV2 encoding a voltage-gated potassium channel subunit cause "cone dystrophy with supernormal rod electroretinogram" in humans.
Am. J. Hum. Genet., 2006 Sep , 79 (574-9).

136

Fantozzi I et al. Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells.
Am. J. Physiol. Lung Cell Mol. Physiol., 2006 Nov , 291 (L993-1004).

137

Tutor AS et al. Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems.
Mol. Biol. Cell, 2006 Nov , 17 (4666-74).

138

Ro S et al. Template switching within exons 3 and 4 of KV11.1 (HERG) gives rise to a 5' truncated cDNA.
Biochem. Biophys. Res. Commun., 2006 Jul 14 , 345 (1342-9).

139

Anderson CL et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
Circulation, 2006 Jan 24 , 113 (365-73).

140

Gómez R et al. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels.
Br. J. Pharmacol., 2005 Sep , 146 (146-61).

141

Borlak J et al. Hallmarks of ion channel gene expression in end-stage heart failure.
FASEB J., 2003 Sep , 17 (1592-608).

142

Ottschytsch N et al. Obligatory heterotetramerization of three previously uncharacterized Kv channel alpha-subunits identified in the human genome.
Proc. Natl. Acad. Sci. U.S.A., 2002 Jun 11 , 99 (7986-91).